Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- ASKA Downwardly Revises Sales Forecast Due to Effects of Quake
October 31, 2011
- Astellas Upwardly Revises Business Forecasts Driven by Vesicare
October 31, 2011
- Abilify Posted US Sales of US$983 Mil. in Jul-Sep
October 31, 2011
- Anti-HIV JTK-303 Applied for Combination Tablet in the US: JT
October 31, 2011
- Losses Increase Due to Fallen Milestone Payments: OncoTherapy
October 31, 2011
- Wakamoto’s Apr-Sep Profits Up 2% on Latanoprost Sales Growth, Recovered Losses
October 31, 2011
- Terumo Posts Record Sales, Operating Profits in First Half FY2012
October 31, 2011
- PI Trial of Darinaparsin Inj. Starts for PTCL: Solasia
October 31, 2011
- MediciNova to Start Repeat Dose PIb Clinical Trial of MN-221 in US
October 31, 2011
- Meiji Seika Pharma Planning to Develop Biosimilars for Infectious Diseases, Cancer, and RA
October 31, 2011
- Medipal HD: Near 90% Decline in Operating Profits
October 31, 2011
- Kyowa Kirin’s Pharmaceutical Business Reports Increases in Sales, Profits in Jan.-Sept. Driven by Nesp
October 28, 2011
- Novartis to Cut 2,000 Jobs in Manufacturing, Development Division
October 28, 2011
- Hisamitsu Forms Chinese Subsidiary to Enter OTC Business
October 28, 2011
- JDF, Eli Lilly Japan Create Subsidy Program for Basic Incretin Research
October 28, 2011
- Nitto Denko, Maruho Apply for Additional Indication for Penles Tape for Pain Relief with Removal of Warts
October 28, 2011
- Bayer to Continue to Discuss Filing for Approval for Regorafenib in Europe, US after Improvement of OS in PIII Trial
October 28, 2011
- Baxter's Worldwide Sales Up 10% to US$10.3 Bil. for 1st Nine Months of 2011
October 28, 2011
- Terumo: Record Sales, Operating Profits in 1st Half of FY2011
October 28, 2011
- Nexium Tops HP Market in September Led by 2 Active Marketers: RepTrack Survey
October 27, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…